Tela Bio director Capper acquires $78,442 in company stock
At a glance
- $TELA today+1.97%last $0.78
- Vs industry peers+0.84 pts6-peer median +1.13% · ahead
- Since Sep 16−39.8%from the first trade after the story
- 52-week range55.0% above low$0.50 – $1.50
- Cash runway~7 mo$22.7M cash ÷ $3.3M/mo burn · 10-Q
- In the headline$78,442Amount
Nothing reported about tela bio across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: $TELA is part of a merger story around $78,442 — the fine print on how it is paid for is where the interesting parts usually hide.
- How the stock is trading: $TELA +1.97% in the latest session.
- Timing: It was published overnight, so the session change shown belongs to a day that had already closed. Market holidays are not detected.
Where the stock stands
TELA Bio ($TELA) added 1.97% to $0.78 in the latest session. Over the past month it is down 19.9%. That leaves it 48% below its 52-week high of $1.50 and 55% above its low of $0.50. The year's high was 3.0 times its low, which makes double-digit swings fairly routine here.
What the filings say
In its latest report (10-Q, filed Nov 10, 2026), $TELA lost $9.3M over the quarter to Sep 30, 2026 on revenue of $19.0M (-1.7% QoQ). Operations used $29.2M of cash over the nine months to Sep 30, 2026 — about $3.3M a month — against $22.7M in cash on Sep 30, 2026. At that pace the cash covers about 7 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. Liabilities of $74.1M exceeded assets of $49.5M on Sep 30, 2026, leaving book equity negative. Figures are as filed with the SEC; the $TELA page has the full statements.
How much coverage it is getting
This story is more than a month old. Since then Wook has filed 2 newer stories on TELA Bio in the last 30 days, 2 of them this week. By their wording, 0 read bullish, 2 neutral and 0 bearish.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $TELA page, and they say what management has disclosed without a reporter in between. Where several outlets agree is usually the news; where they differ is the angle. Wook AI, at the top of the page, can work out how far $TELA is from its high or compare this week's coverage with earlier weeks.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on September 17, 2026. $TELA has moved -39.80% ($1.29 to $0.78). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
